Peptides That Increase Testosterone: Mechanisms, Candidates, and Research

How upstream signaling peptides interact with the hypothalamic-pituitary-gonadal axis, and what the research actually supports.

Testosterone is not a peptide. It is a steroid hormone, made from cholesterol inside the Leydig cells of the testes. That distinction matters because the phrase "peptides that increase testosterone" describes something specific. These peptides are short signaling molecules. They act upstream of testosterone production. They tell the body to make more of its own testosterone.

They do not replace testosterone. They do not deliver it. Like other signaling peptides, they influence the signaling pathway that controls how much the body produces.

That pathway is called the hypothalamic-pituitary-gonadal axis, or HPG axis. Every peptide tied to natural testosterone elevation works somewhere along this circuit. Understanding the circuit is the first step. It is what separates real candidates from misclassified compounds, and what shows where the evidence is solid versus where it is still preliminary.

How the HPG Axis Controls Testosterone

The HPG axis is a feedback loop with three stages. Here is how it moves:

The loop also has a brake. Testosterone and its conversion product, estradiol, feed back to the hypothalamus and pituitary. That feedback slows the upstream signal. It is how the body keeps testosterone in a normal range.

A few things can disrupt this loop:

• If GnRH pulses become irregular, LH output falls.
• If LH falls, testosterone production drops.
• If testosterone is added from outside the body, the loop senses excess and shuts down GnRH and LH.

That last point matters. It is why long-term testosterone replacement therapy can shrink the testes and reduce fertility. The body stops producing its own — one reason researchers focused on testosterone and mitochondrial vitality often look at upstream alternatives before considering full replacement.

Gonadorelin: Synthetic GnRH

Gonadorelin is a synthetic peptide. Its structure is identical to natural GnRH. The mechanism is direct.

• It binds to GnRH receptors on the pituitary.
• The pituitary releases LH and FSH.
• LH then signals the testes to produce testosterone.
• 
  

Because gonadorelin copies the body's own starting hormone, it acts at the most upstream point of the axis.

Gonadorelin has a long clinical history. It has been used to:

• Test pituitary function in medical settings
• Support fertility protocols
• Maintain testicular activity during certain hormonal interventions

There is one important detail about how it works. GnRH is naturally pulsed. The pituitary responds to that rhythm. If gonadorelin is given continuously instead of in pulses, the receptors can become desensitized. In that case, LH and FSH actually drop. This is the same principle behind GnRH agonist medications used to suppress testosterone in some clinical cases.

In other words, the direction of the effect depends on how it is given, not just whether it is given.

Kisspeptin and the Upstream Trigger

Kisspeptin sits one step further upstream than GnRH. It is a neuropeptide made in the hypothalamus. Its job is to trigger GnRH release.

Without kisspeptin, the system does not start. People with mutations in the kisspeptin receptor do not progress through puberty. Their testosterone stays at prepubertal levels.

That makes kisspeptin one of the most central peptides in the testosterone pathway. Research interest has focused on:

• Healthy men: Short studies show kisspeptin and its shorter form, kisspeptin-10, raise LH, FSH, and testosterone.
• Men with hypogonadotropic hypogonadism: Researchers have explored whether kisspeptin can restart HPG axis function when the loop is intact but understimulated.
• Broader effects: Studies have looked at kisspeptin's role in sexual response, reproductive timing, and the link between mood, metabolism, and reproductive function.

What kisspeptin does in short-term studies is fairly clear. What is missing is long-term human trial data. As of now, kisspeptin remains an investigational compound. Short-term hormone responses do not automatically translate into safe long-term protocols.

hCG: A Glycoprotein That Mimics LH

Human chorionic gonadotropin, or hCG, is often grouped with peptides. The classification is not exact. hCG is a glycoprotein hormone, not a short-chain peptide. It is much larger and more complex than gonadorelin or kisspeptin.

What matters at the receptor level is the similarity. hCG looks enough like LH that it binds to LH receptors on Leydig cells. Once bound, it stimulates testosterone production directly.

This is what makes hCG behave differently from the other two:

hCG is used in male fertility protocols. It is also used to keep the testes active during periods when LH signaling is suppressed.

The trade-off is that hCG does not exercise the upper parts of the HPG axis. It bypasses the hypothalamus and pituitary. If the goal is to maintain or restore the full loop, hCG only addresses one part of it.

Peptides Often Misclassified as Testosterone Boosters

Here is why each one is often misunderstood:

• BPC-157 and TB-500: BPC-157 is a synthetic fragment from a protein found in gastric juice. TB-500 is a synthetic version of part of thymosin beta-4. Both are studied for repair and recovery applications, not testosterone modulation. Neither has a documented testosterone mechanism. Anecdotal reports of better energy or recovery do not equal hormonal effects.
  
  
• Ipamorelin, CJC-1295, GHRP-6: These act on growth hormone-releasing pathways. Their downstream output is growth hormone and IGF-1, not testosterone. Some users report broader well-being effects. These are likely indirect, tied to better sleep, recovery, or body composition.
  
  

To qualify as a peptide that increases testosterone in the strict sense, a compound has to either work through the HPG axis or stimulate Leydig cells directly. Compounds that produce favorable side effects without engaging this pathway belong to different categories.

What the Research Actually Shows

The published evidence is not equal across all of these compounds. Here is a clearer breakdown:

A few details worth noting:

• Gonadorelin has solid evidence for its ability to trigger LH and FSH release. Its use to optimize testosterone in men without diagnosed conditions is less well documented. Long-term outcome data for that use case is limited.
  
  
• Kisspeptin shows consistent short-term hormonal effects in studies. Trials in men with hypothalamic forms of hypogonadism have shown promising responses. The gap is in long-duration safety and efficacy data.
  
  
• hCG has the most complete clinical record. Its use outside of fertility medicine and testicular function maintenance is less well supported.
  
  

For the broader question of whether upstream peptides offer durable, safe, meaningful testosterone elevation in healthy men, the honest answer is that the evidence does not yet exist at the level needed for confident population-level claims. Research is active. Long-term outcome data is not.

Safety and the Risk of Disrupting the System

These peptides are not low-consequence compounds. The HPG axis is a feedback system. Feedback systems respond to overstimulation as much as understimulation.

Key safety considerations include:

• GnRH analogs given continuously instead of pulsed can desensitize pituitary receptors. The result is suppression of LH and FSH, the opposite of the intended effect.
  
  
• Long-term kisspeptin use has not been fully characterized. Tolerance and downregulation patterns are not well mapped.
  
  
• Sustained hCG use can suppress the body's own LH through feedback. This happens especially at higher doses or with extended administration.
  
  

There are also downstream considerations tied to elevated testosterone itself, regardless of how it is reached:

• Erythrocytosis: Elevated red blood cell concentration is a known consequence of supraphysiological testosterone.
• Aromatization: Some testosterone converts to estradiol, which can produce associated effects.
• Feedback suppression: Even peptides that look benign can produce the same long-term suppression as direct testosterone if pushed beyond physiological ranges.

Regulatory status also matters. These compounds are not approved as general wellness or testosterone optimization therapies in most jurisdictions. They are research peptides, which means sourcing standards vary widely — vetted research peptide vendors publish lot-specific Certificates of Analysis and third-party verification, and that documentation is the baseline for any serious evaluation. In the case of hCG and gonadorelin, they are prescription medications used in defined clinical settings.

Why Endogenous Stimulation Is Different from Replacement

The interest in upstream peptides exists because direct testosterone replacement, while clinically established, has trade-offs:

Some men prefer working with the body's own production. Reasons include:

• Concerns about preserving fertility
• Avoiding HPG axis suppression
• Preference for a more physiological approach

Whether upstream peptides actually deliver on this premise in a sustained, safe, and meaningful way is the open question. The mechanisms are real. The signaling pathways are well mapped. Short-term hormonal responses are documented. Long-term human outcome data is what is mostly missing.

Two ideas need to sit alongside each other:

• The mechanisms are coherent.
• The evidence base for durable use is incomplete.

Holding both at once is the most honest way to evaluate this category.

If you are evaluating peptide research and want to think carefully through the HPG axis before making decisions, structured guidance can help separate mechanism from marketing. Project Biohacking offers private 1:1 coaching focused on research literacy and risk-aware decision-making for biohackers navigating peptides at the edge of established evidence.

Peptides That Increase Testosterone FAQs

References

HPG Axis and GnRH Pulsatility

1. Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression. Molecular and Cellular Endocrinology. 2018. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5722688/
2. Tsutsumi R, Webster NJG. GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocrine Journal. 2009. https://www.jstage.jst.go.jp/article/endocrj/56/6/56_K09E-185/_article
3. Counis R, et al. Decoding high gonadotropin-releasing hormone pulsatility: a role for GnRH receptor coupling to the cAMP pathway? Frontiers in Endocrinology. 2012. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431540/
4. de Koning J, et al. The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone. Frontiers in Endocrinology. 2023. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201305/

Gonadorelin

1. Padula AM. GnRH analogues — agonists and antagonists. Animal Reproduction Science. 2005. ScienceDirect: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gonadorelin-associated-peptide
2. Zhang L, et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. American Journal of Men's Health. 2019.

Kisspeptin

1. Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism. 2005. PubMed: https://pubmed.ncbi.nlm.nih.gov/16174713/
2. George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. Journal of Clinical Endocrinology & Metabolism. 2011. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3380939/
3. Narayanaswamy S, et al. Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with body mass index. Clinical Endocrinology. 2016.
4. Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction. 2015. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507333/
5. Mumtaz A, et al. Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men. Andrologia. 2019. PubMed: https://pubmed.ncbi.nlm.nih.gov/30590872/
6. Lippincott MF, et al. Acquisition of kisspeptin responsiveness is key to reversal of hypogonadotropic hypogonadism. Nature Reviews Endocrinology. 2016. https://www.nature.com/articles/nrendo.2016.95
7. Skorupskaite K, et al. Kisspeptin system — physiology and clinical perspectives. European Journal of Internal Medicine. 2025. ScienceDirect: https://www.sciencedirect.com/science/article/pii/S000342662500112X
8. Trevisan CM, et al. Kisspeptins regulating fertility: potential future therapeutic approach in infertility treatment. International Journal of Molecular Sciences. 2025. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12112093/

hCG (Human Chorionic Gonadotropin)

1. La Vignera S, et al. Human chorionic gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone above 300 ng/dL. Translational Andrology and Urology. 2019. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC6844348/
2. Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Translational Andrology and Urology. 2018. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC6087849/
3. Casarini L, et al. Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro. Reproductive Biology and Endocrinology. 2016. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5217336/
4. Habous M, et al. Human chorionic gonadotropin therapy in hypogonadic severe-oligozoospermic men and its effect on semen parameters. World Journal of Men's Health. 2022. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8923634/

TRT and HPG Axis Suppression

1. Crosnoe LE, et al. Exogenous testosterone: a preventable cause of male infertility. Translational Andrology and Urology. 2013. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4708215/
2. Patel AS, et al. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology. 2016. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4854084/
3. Desai A, et al. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy and anabolic-androgenic steroids. Therapeutic Advances in Urology. 2022. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9243576/
4. Lo EM, et al. Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects. Sexual Medicine Reviews. 2018. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7894643/
5. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018.
6. Punjani N, et al. Testosterone replacement therapy and spermatogenesis in reproductive age men. Nature Reviews Urology. 2025. https://www.nature.com/articles/s41585-025-01032-8

Testosterone-Induced Erythrocytosis

1. Bachman E, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. Journals of Gerontology Series A. 2014. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4022090/
2. Jones SD Jr, et al. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sexual Medicine Reviews. 2015. PubMed: https://pubmed.ncbi.nlm.nih.gov/27784544/
3. Ohlander SJ, et al. Erythrocytosis following testosterone therapy. Sexual Medicine Reviews. 2018.
4. Albasri A, et al. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocrine Connections. 2024. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11466264/

BPC-157 (Tissue Repair, Not Testosterone)

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275860/
2. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. Biomedicines. 2022. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775659/
3. Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/

TB-500 / Thymosin Beta-4 (Tissue Repair, Not Testosterone)

1. Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.
2. Crockford D, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. 2010.
3. Sosne G, et al. Thymosin beta 4: a novel regenerative tissue repair molecule. Annals of the New York Academy of Sciences. 2010.

Ipamorelin, CJC-1295, and Growth Hormone Secretagogues (GH Pathway, Not Testosterone)

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.
2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006. PubMed: https://pubmed.ncbi.nlm.nih.gov/16352683/
3. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018.
4. Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews. 1997.